Serum SIRT3 Levels in Epilepsy Patients and Its Association with Clinical Outcomes and Severity: A Prospective Observational Study

Overview

Journal Open Med (Wars)

Specialty General Medicine

Date 2024 Aug 2

PMID 39091611

Authors

Yun Hu

Ting Zhou

Qingye Li

Affiliations

Soon will be listed here.

Abstract

Objective: In this prospective observational study, we aimed to investigate the serum levels of sirtuin (SIRT)3 in epilepsy patients and its association with the severity of the disease.

Methods: This prospective observational study included 203 patients with symptomatic epilepsy and 100 healthy controls who visited our hospital from November 2019 to November 2022. The severity of the disease in epilepsy patients was assessed using the National Hospital Seizure Severity Scale (NHS3). We used enzyme-linked immunosorbent assay to measure the serum levels of SIRT3, interleukin (IL)-6, IL-1β, tumor necrosis factor-alpha, and C-reactive protein in all patients. In addition, the cognitive function of all study participants was evaluated using the Mini-Mental State Examination and the Montreal Cognitive Assessment (MOCA). All data were analyzed using SPSS 25.0 software.

Results: The MOCA scores of the epilepsy patients were significantly lower compared to the healthy volunteers ( < 0.05). The serum SIRT3 levels were decreased significantly in patients with refractory epilepsy (183.16 ± 17.22 pg/mL) compared to non-refractory epilepsy patients (199.00 ± 18.68 pg/mL). In addition, serum SIRT3 levels were negatively correlated with the inflammatory factors IL-6 (Pearson's correlation -0.221, = 0.002) and NHS score (Pearson's correlation -0.272, < 0.001) of epilepsy patients, while positively correlated with MOCA scores (Pearson's correlation 0.166, = 0.018). Furthermore, the receiver operating characteristic curve demonstrated that serum SIRT3 could be used to diagnose epilepsy, as well as refractory epilepsy. Finally, logistic regression analysis showed that SIRT3 (OR = 1.028, 95%CI: 1.003-1.054, = 0.028), IL-6 (OR = 0.666, 95%CI: 0.554-0.800, < 0.001), IL-1β (OR = 0.750, 95%CI: 0.630-0.894, = 0.001), and NHS3 (OR = 0.555, 95%CI: 0.435-0.706, < 0.001) were risk factors for refractory epilepsy.

Conclusion: In conclusion, our findings demonstrated that serum SIRT3 levels were significantly decreased in epilepsy patients and further decreased in patients with refractory epilepsy. This study might provide new therapeutic targets and comprehensive treatment strategies for epilepsy patients.

References

Liu Q, Sun Y, Huang H, Chen C, Wan J, Ma L . Sirtuin 3 protects against anesthesia/surgery-induced cognitive decline in aged mice by suppressing hippocampal neuroinflammation. J Neuroinflammation. 2021; 18(1):41. PMC: 7863360. DOI: 10.1186/s12974-021-02089-z. View

Vezzani A, French J, Bartfai T, Baram T . The role of inflammation in epilepsy. Nat Rev Neurol. 2010; 7(1):31-40. PMC: 3378051. DOI: 10.1038/nrneurol.2010.178. View

Zhang P, Zhao T, Zhou W . The Clinical Significance of SIRT3 in COVID-19 Patients: A Single Center Retrospective Analysis. Ann Clin Lab Sci. 2021; 51(5):686-693. View

Xing J, Han D, Xu D, Li X, Sun L . CREB Protects against Temporal Lobe Epilepsy Associated with Cognitive Impairment by Controlling Oxidative Neuronal Damage. Neurodegener Dis. 2020; 19(5-6):225-237. DOI: 10.1159/000507023. View

Berg A, Vickrey B, Testa F, Levy S, Shinnar S, DiMario F . How long does it take for epilepsy to become intractable? A prospective investigation. Ann Neurol. 2006; 60(1):73-9. DOI: 10.1002/ana.20852. View

Scheffer I, Berkovic S, Capovilla G, Connolly M, French J, Guilhoto L . ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4):512-521. PMC: 5386840. DOI: 10.1111/epi.13709. View

Jiang D, Wang Y, Li M, Ma Y, Wang Y . SIRT3 in Neural Stem Cells Attenuates Microglia Activation-Induced Oxidative Stress Injury Through Mitochondrial Pathway. Front Cell Neurosci. 2017; 11:7. PMC: 5281640. DOI: 10.3389/fncel.2017.00007. View

Holler Y, Butz K, Thomschewski A, Schmid E, Hofer C, Uhl A . Prediction of Cognitive Decline in Temporal Lobe Epilepsy and Mild Cognitive Impairment by EEG, MRI, and Neuropsychology. Comput Intell Neurosci. 2020; 2020:8915961. PMC: 7256687. DOI: 10.1155/2020/8915961. View

Wang D, Cao L, Zhou X, Wang G, Ma Y, Hao X . Mitigation of honokiol on fluoride-induced mitochondrial oxidative stress, mitochondrial dysfunction, and cognitive deficits through activating AMPK/PGC-1α/Sirt3. J Hazard Mater. 2022; 437:129381. DOI: 10.1016/j.jhazmat.2022.129381. View

10.

Gao J, Zhang X, Shu G, Chen N, Zhang J, Xu F . Trilobatin rescues cognitive impairment of Alzheimer's disease by targeting HMGB1 through mediating SIRT3/SOD2 signaling pathway. Acta Pharmacol Sin. 2022; 43(10):2482-2494. PMC: 9525711. DOI: 10.1038/s41401-022-00888-5. View

11.

Singh A, Trevick S . The Epidemiology of Global Epilepsy. Neurol Clin. 2016; 34(4):837-847. DOI: 10.1016/j.ncl.2016.06.015. View

12.

Marcus J, Andrabi S . SIRT3 Regulation Under Cellular Stress: Making Sense of the Ups and Downs. Front Neurosci. 2018; 12:799. PMC: 6224517. DOI: 10.3389/fnins.2018.00799. View

13.

Berilgen M, Mungen B, Ustundag B, Demir C . Serum ghrelin levels are enhanced in patients with epilepsy. Seizure. 2006; 15(2):106-11. DOI: 10.1016/j.seizure.2005.11.008. View

14.

Liang K, Mu R, Liu Y, Jiang D, Jia T, Huang Y . Increased Serum S100B Levels in Patients With Epilepsy: A Systematic Review and Meta-Analysis Study. Front Neurosci. 2019; 13:456. PMC: 6532535. DOI: 10.3389/fnins.2019.00456. View

15.

Wu G, Liu J, Li S, Gao W, Qiu M, Yang C . Glycyrrhizic acid protects juvenile epileptic rats against hippocampal damage through activation of Sirtuin3. Brain Res Bull. 2020; 164:98-106. DOI: 10.1016/j.brainresbull.2020.08.008. View

16.

Liu J, Zhou G, Chen R, Tong Z, Zhang H, Wang X . Mitochondrial Sirt3 serves as a biomarker for sepsis diagnosis and mortality prediction. Sci Rep. 2022; 12(1):10414. PMC: 9213502. DOI: 10.1038/s41598-022-14365-w. View

17.

Anamika , Khanna A, Acharjee P, Acharjee A, Trigun S . Mitochondrial SIRT3 and neurodegenerative brain disorders. J Chem Neuroanat. 2017; 95:43-53. DOI: 10.1016/j.jchemneu.2017.11.009. View

18.

Uludag I, Duksal T, Tiftikcioglu B, Zorlu Y, Ozkaya F, Kirkali G . IL-1β, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure. 2015; 26:22-5. DOI: 10.1016/j.seizure.2015.01.009. View

19.

Lin Z, Fang D . The Roles of SIRT1 in Cancer. Genes Cancer. 2013; 4(3-4):97-104. PMC: 3764469. DOI: 10.1177/1947601912475079. View

20.

Allen A, Jones A, LoBianco F, Krager K, Aykin-Burns N . Effect of Sirt3 on hippocampal MnSOD activity, mitochondrial function, physiology, and cognition in an aged murine model. Behav Brain Res. 2023; 444:114335. PMC: 10081808. DOI: 10.1016/j.bbr.2023.114335. View